Jump to content

David Lodge (scientist)

Add links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by 2600:1005:b053:c77d:b129:deea:725d:a18f (talk) at 23:41, 10 August 2016. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

For other people named David Lodge, see David Lodge.
David Lodge
Scientific career
Doctoral advisorTim Biscoe
Other academic advisorsDavid Curtis
Websitewww.bris.ac.uk/synaptic/people/david-lodge/

David Lodge FRS[1] is a Research Fellow in the Department of Physiology and Pharmacology at the University of Bristol.[2][3]

Education

Lodge was awarded a Bachelor of Veterinary Science degree in 1963 and worked in University of Bristol as a surgeon and anaesthetist, before postgraduate research with Tim J. Biscoe[4] on the neuropharmacology of amino acids, he was awarded his PhD in 1974.

Research and career

During postdoctoral studies at the Australian National University with David Curtis FRS, he helped establish the role of glutamate as a central neurotransmitter and characterised its actions between AMPA, N-Methyl-D-aspartic acid (NMDA) and kainate receptor subtypes. At the Royal Veterinary College, Lodge linked his interests in anaesthesia and glutamate receptors by making the key discovery that the dissociative anaesthetics, ketamine and phencyclidine,[5] selectively blocked NMDA receptors. He related NMDA receptor antagonism to psychotomimetic effects. This provided a basis for the glutamate hypothesis of schizophrenia and redirected pharmaceutical search for schizophrenia therapies. David was recruited as a director of Eli Lilly’s neuroscience program, where he helped develop glutamate receptor approaches to brain diseases, resulting in clinical trials, e.g. for schizophrenia, some of which are ongoing. As of 2016, Lodge’s research concerns the mechanism of action of new ‘legal highs’ and the consequences of spontaneous mutations in glutamate receptors.[1]

Awards and honours

Lodge was elected a Fellow of the Royal Society (FRS) in 2016[1] and a Fellow of the Academy of Medical Sciences.[when?]

References

  1. ^ a b c "Dr David Lodge FMedSci FRS". London: Royal Society. Archived from the original on 2016-04-29. One or more of the preceding sentences incorporates text from the royalsociety.org website where:

    “All text published under the heading 'Biography' on Fellow profile pages is available under Creative Commons Attribution 4.0 International License.” --Archived 2015-09-25 at the Wayback Machine
  2. ^ David Lodge's publications indexed by the Scopus bibliographic database. (subscription required)
  3. ^ "Professor David Lodge, MRC Centre for Synaptic Plasticity". Bristol: bris.ac.uk. Archived from the original on 2016-05-21.
  4. ^ T. J. Biscoe, A. W. Duggan & D. Lodge (1972). "Effect of etorphine, morphine and diprenorphine on neurones of the cerebral cortex and spinal cord of the rat". British Journal of Pharmacology. 46 (2): 201–212. PMC 1666335. PMID 4405610.
  5. ^ Lodge, D; Mercier, M S (2015). "Ketamine and phencyclidine: the good, the bad and the unexpected". British Journal of Pharmacology. 172 (17): 4254–4276. doi:10.1111/bph.13222. PMID 26075331.
Stub icon

This article about a British scientist is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=David_Lodge_(scientist)&oldid=733921403"